These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16880737)

  • 1. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
    Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
    Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells.
    Li Z; Yao H; Guin S; Padhye SS; Zhou YQ; Wang MH
    Int J Oncol; 2010 Aug; 37(2):473-82. PubMed ID: 20596675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
    Wang MH; Lao WF; Wang D; Luo YL; Yao HP
    Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.
    Guin S; Yao HP; Wang MH
    Mol Pharm; 2010 Apr; 7(2):386-97. PubMed ID: 20039696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
    Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
    Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of cytoplasmic {beta}-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase.
    Xu XM; Zhou YQ; Wang MH
    J Biol Chem; 2005 Jul; 280(26):25087-94. PubMed ID: 15878878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor Tyrosine Kinase.
    Ma Q; Zhang K; Guin S; Zhou YQ; Wang MH
    Mol Cancer; 2010 Nov; 9():307. PubMed ID: 21114864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
    J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential.
    Zhou YQ; He C; Chen YQ; Wang D; Wang MH
    Oncogene; 2003 Jan; 22(2):186-97. PubMed ID: 12527888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
    Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
    Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
    Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
    Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
    Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
    Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.
    Suthe SR; Yao HP; Weng TH; Wang MH
    Curr Cancer Drug Targets; 2023; 23(2):103-117. PubMed ID: 36028965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.
    Tong X; Zhang X; Fan J; Tong Y; Li S; Jin J; Yao H
    Cancer Biol Ther; 2013 Apr; 14(4):370-7. PubMed ID: 23360784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160.
    Lu Y; Yao HP; Wang MH
    J Exp Clin Cancer Res; 2008 Oct; 27(1):55. PubMed ID: 18950514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
    Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
    Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo.
    Zhang Y; Kaplan-Lefko PJ; Rex K; Yang Y; Moriguchi J; Osgood T; Mattson B; Coxon A; Reese M; Kim TS; Lin J; Chen A; Burgess TL; Dussault I
    Cancer Res; 2008 Aug; 68(16):6680-7. PubMed ID: 18701492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
    Wang MH; Padhye SS; Guin S; Ma Q; Zhou YQ
    Acta Pharmacol Sin; 2010 Sep; 31(9):1181-8. PubMed ID: 20694025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic anti-cancer activity of antibodies targeting sulfhydryl bond constrained epitopes on unglycosylated RON receptor tyrosine kinase.
    Koh XY; Koh XH; Hwang LA; Ferrer FJ; Rahmat SAB; Lama D; Lane DP
    Oncogene; 2019 Nov; 38(48):7342-7356. PubMed ID: 31417186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.